An Active Surveillance, Post Authorization Safety Study (PASS) to Investigate Relevant Safety Outcomes among Patients Treated with Flixabi for Rheumatoid Arthritis (RA) within the German Registry Rheumatoide Arthritis: Beobachtung der Biologika-Therapie (RABBIT)

Data sources

• Data source(s), other:
  biologics registry RABBIT
• Data sources (types):
  Drug registry

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No